Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Long-Term Debt Repayments (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Long-Term Debt Repayments for 10 consecutive years, with $66.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $66.7 million, compared with a TTM value of $66.7 million through Dec 2025, up 44765100.0%, and an annual FY2025 reading of $201.6 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $66.7 million for Q4 2025 at Arrowhead Pharmaceuticals, up from -$150.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $66.7 million in Q4 2025 and bottomed at $66.7 million in Q4 2025.